SCHEDULE: EdgePoint Investment Group Holds 4.21% Stake in Twist Bioscience

EdgePoint Investment Group Inc. has disclosed a beneficial ownership of 4.21% of Twist Bioscience Corp.'s common stock as of June 30, 2026.

Summary

• EdgePoint Investment Group Inc. has filed a Schedule 13G, indicating its beneficial ownership of Twist Bioscience Corp. common stock.
• As of June 30, 2026, EdgePoint beneficially owned 2,521,635 shares, representing 4.21% of the class of securities.
• This ownership includes sole voting power over 1,945,483 shares and shared voting power over 576,152 shares.
• EdgePoint also has sole dispositive power over 1,945,483 shares and shared dispositive power over 576,152 shares.
• The filing confirms that these securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but not overwhelming stake in Twist Bioscience Corp by EdgePoint Investment Group Inc. The filing primarily confirms an existing investment position rather than announcing new strategic moves.

Positives

• EdgePoint Investment Group Inc. holds a substantial stake of 4.21% in Twist Bioscience Corp., suggesting confidence in the company's long-term prospects.
• The filing indicates that the shares are held in the ordinary course of business, implying a stable, long-term investment strategy rather than a short-term speculative play.

Negatives

• The filing does not disclose any new strategic initiatives or significant changes in ownership, suggesting a status quo rather than a new development.

Risks

• The filing does not explicitly mention any new risks or challenges related to Twist Bioscience Corp. or EdgePoint's investment strategy.

Future Outlook

The filing does not contain forward-looking statements or specific guidance regarding future performance. It primarily reports on current ownership status.

Management Comments

• EdgePoint Investment Group Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that this filing by a significant investment manager like EdgePoint Investment Group Inc. underscores the ongoing institutional interest in the synthetic biology sector, where Twist Bioscience Corp. operates. Such filings are common for institutional investors tracking their holdings in publicly traded companies.

Comparison to Industry Standards

• As a Schedule 13G filing, this is a standard disclosure for institutional investors exceeding a 5% ownership threshold (or in this case, reporting a change or confirming a significant stake).
• The 4.21% ownership by EdgePoint is a notable stake for an institutional investor in a company like Twist Bioscience Corp., which is positioned in the rapidly evolving synthetic biology market.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's continued interest, which can be viewed positively for stock stability and potential future growth.
• Management: The filing reinforces that the current ownership is not aimed at influencing control, suggesting a focus on long-term value creation.

Next Steps

• EdgePoint Investment Group Inc. will continue to hold its shares in Twist Bioscience Corp. in the ordinary course of business.
• Future filings will be made if EdgePoint's ownership stake changes significantly.

Key Dates

Keywords

Twist Bioscience, EdgePoint Investment Group, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Institutional Investor